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SUMMARY (497 words) 
Background The human monoclonal antibody otilimab inhibits granulocyte-macrophage colony-stimulating 
factor (GM-CSF), a key driver in immune-mediated inflammatory conditions. We evaluated the efficacy, safety, 
and key patient-reported outcomes related to pain of otilimab in patients with active rheumatoid arthritis (RA).  
Methods This Phase IIb, dose-ranging, multicentre, placebo-controlled study was conducted at 64 sites across 
14 countries. Patients aged ≥18 years with RA and receiving stable methotrexate were randomised (1:1:1:1:1:1) 
to subcutaneous placebo or otilimab 22ꞏ5, 45, 90, 135 or 180 mg, plus methotrexate, once weekly for 5 weeks, 
then every other week until week 50. The randomisation schedule was generated by the sponsor and patients 
assigned to treatment via interactive response technology. Randomisation was blocked (block size of six) but 
was not stratified. Investigators, patients, and the sponsor were blinded to treatment. An unblinded administrator 
prepared and administered the study drug. The primary endpoint was DAS28(CRP) <2ꞏ6 at week 24. Patients 
not in the otilimab 180 mg group, without a good/moderate European League Against Rheumatism response 
(week 12) or with disease activity score for 28 joints with C-reactive protein (DAS28[CRP]) >3ꞏ2 (week 24) 
escaped to otilimab 180 mg; those who escaped were treated as non-responders in their original randomised 
group. Safety endpoints were incidence of adverse events (AEs) and serious AEs (SAEs), infections and 
pulmonary events. Efficacy and safety outcomes were assessed in the intent-to-treat population. The study is 
complete (ClinicalTrials.gov NCT02504671). 
Findings Between 23 July 2015 and 29 December 2017, 222 patients were randomised (n=37/group). At weeks 
12 and 24, 86/175 (49ꞏ1%) and 57/83 (68ꞏ7%) escaped to otilimab 180 mg, respectively. At week 24, rates of 
DAS28(CRP) <2ꞏ6 were: 2/37 (5%), 6/37 (16%), 7/37 (19%), 5/37 (14%), and 5/37 (14%) in otilimab 22ꞏ5 mg, 
45 mg, 90 mg, 135 mg, and 180 mg, respectively; 1/37 (3%) in the placebo group. The largest difference was 
achieved with otilimab 90 mg (16ꞏ2%; odds ratio [OR] 8ꞏ39; 95% confidence interval [CI] for OR 0ꞏ98, 72ꞏ14; 
p=0ꞏ0527). Across otilimab dose groups, AEs were reported pre-escape in 19–24 (51–65%) patients and post 
escape in 10–17 (40–61%) patients; in the placebo group this was 18/27 (27%) and 22/26 (50%), respectively. 
The most common AE was nasopharyngitis: pre-escape n=3–9 (8–24%) in otilimab groups, n=1 (1%) in the 
placebo group; post escape n=1–3 (4–10%) in otilimab groups, n=7 (21%) in the placebo group. Pre-escape 
SAEs were foot fracture (otilimab 45 mg); arthralgia, myocardial infarction, dizziness (otilimab 90 mg); 
oesophageal spasm, acute pyelonephritis (otilimab 22ꞏ5 mg), uterine leiomyoma (otilimab 135 mg), and 
dizziness. Post-escape SAEs were ankle fracture (placebo) and RA (otilimab 135 mg). There were no deaths or 
pulmonary events of clinical concern, and rates of serious infection were low.  
Interpretation Otilimab plus methotrexate was well tolerated and despite not achieving the primary endpoint of 
DAS28(CRP) remission there were improvements compared with placebo in disease activity scores. Of 
particular note, patients reported significant improvement in pain and physical function, supporting further 
clinical development of otilimab in RA. 
Funding GlaxoSmithKline. 






Research in context 
Evidence before this study 
We searched PubMed with the terms “rheumatoid arthritis” AND “mavrilimumab” OR “namilumab” OR 
“MOR103” OR “anti-GM-CSF” OR “anti-GMCSF”, with no restriction on language, for articles published 
between 2000 and 2015, i.e. prior to study start. We identified 4 clinical trials: one proof-of-concept Phase Ib/IIa 
trial of otilimab (MOR103) and 3 Phase I/II/IIa trials for mavrilimumab. Both agents showed evidence of 
efficacy for targeting granulocyte-macrophage colony-stimulating factor (GM-CSF) or its receptor in patients 
with rheumatoid arthritis (RA). Together with the strong preclinical evidence of a role for GM-CSF in the 
pathology of RA, and a need for alternative therapy options for RA, these findings supported the rationale to 
pursue the clinical development of otilimab, a monoclonal antibody that binds to and inhibits human GM-CSF. 
Furthermore, only one of the previous studies included assessment of patient-reported outcomes (PROs) beyond 
Health Assessment Questionnaire-Disability Index (HAQ-DI). In the Phase Ib/IIa otilimab study, Functional 
Assessment of Chronic Illness Therapy (FACIT)-Fatigue and pain Visual Analogue Scale (VAS) were also 
assessed; all PROs showed improvement following treatment with otilimab compared with placebo. The 
inclusion of a range of PROs in clinical studies is becoming increasingly important due to the chronic, long-term 
debilitating nature of the disease and ongoing disability for patients despite optimised clinical therapy. As such, 
a wider assessment of the impact of anti-GM-CSF treatment on PROs in RA was required.   
Added value of this study 
To our knowledge, this is the first clinical trial in the field of rheumatology with a novel study design offering 
an automated and blinded escape to a higher dose to patients with RA who had not obtained a meaningful 
benefit from their randomised treatment, with the aim to achieve an optimised ‘treat-to-target’ dosing regimen. 
We observed dose-related and meaningful clinical benefit with otilimab in patients with an inadequate response 
to methotrexate. Otilimab treatment led to rapid reduction in tender and swollen joint counts and hence Clinical 
Disease Activity Index scores. This is also (to our knowledge) the first clinical trial assessing an anti-GM-CSF 
antibody in RA to include a wide panel of PROs: HAQ-DI, pain VAS, short-form health survey and 
components, FACIT-Fatigue, Brief Fatigue Inventory – Question 3, and Patient’s Global Assessment of 
Arthritis Disease Activity. We observed substantial improvement in a range of these PRO measures, particularly 
in pain scores. Otilimab treatment was well tolerated and no significant unexpected safety findings were 
observed. 
Implications of all the available evidence 
The results of this study build on the existing data and support a positive benefit:risk profile of treatment with 
otilimab in active RA and provide a basis for further clinical development. Interestingly, the temporal changes 
in pain compared with the temporal changes in disease activity, including acute phase reactants (C-reactive 






Many patients with rheumatoid arthritis (RA) have an inadequate response to currently available disease-
modifying therapies1 with few achieving disease remission. Even when disease activity is reduced many patients 
continue to experience clinically significant pain, despite the availability of ‘gold standard’ treatments that 
suppress disease-associated inflammation and damage.2 Thus, there is an impetus to investigate new treatments 
in RA that target pain as well as inflammation and damage, and explore whether disease activity, clinical 
remission, and pain are always associated or can be dissociated mechanistically and clinically.  
In pathological conditions, granulocyte-macrophage colony-stimulating factor (GM-CSF)3 is a key driver of 
inflammation, pain, and tissue damage in a range of immune-mediated disease states.3-5 Levels of GM-CSF are 
elevated in the synovial tissue of some patients with RA6,7 and GM-CSF augments myeloid cell activation,8 
leading to production of inflammatory cytokines such as interleukin (IL)-6, IL-1, tumour necrosis factor (TNF) 
and chemokine (c-c motif) ligand 17 (CCL17), which are associated with pain and can result in severe tissue 
damage.3,9 Mechanistic studies indicate that GM-CSF is involved in the development of pain-like behaviour in 
mouse models of inflammatory pain and arthritis,5,10 and a mouse sarcoma model demonstrated a role for GM-
CSF in sensitising sensory nerves.11 Therefore, anti-GM-CSF agents could have a key role in treating 
inflammation and pain in multiple conditions, including RA.8,10 
Otilimab (also known as GSK3196165, MOR103, and MOR04357) is a high-affinity recombinant human 
monoclonal immunoglobulin G1 antibody that specifically binds to human GM-CSF, inhibiting its activity.12 
Phase I/II clinical trials in patients with RA indicated that inhibition of GM-CSF signalling by human 
monoclonal antibodies, including otilimab, leads to clinical benefit with a reduction in disease activity. 13-16 
This randomised, Phase IIb, double-blind, placebo-controlled, dose-ranging study assessed clinical responses, 
including inflammation and pain, across five doses of otilimab in combination with methotrexate (MTX) in 
patients with active, moderate-to-severe RA who had an inadequate response to MTX. The primary endpoint 
was the induction of disease remission. Other outcomes included suppression of inflammation and improvement 
in pain, in addition to other patient-reported outcome (PRO) measures recommended by American College of 
Rheumatology (ACR) and European League Against Rheumatism (EULAR).17,18 The trial design included an 
innovative feature of blinded escape to otilimab 180 mg based on the stringent criteria of good/moderate 
EULAR response at week 12, or on disease activity score for 28 joints with C-reactive protein (DAS[CRP]) 
>3ꞏ2 at week 24. 
METHODS 
Study design 
This randomised, Phase IIb, dose-ranging, multicentre, double-blind, parallel-group, placebo-controlled study 
(Appendix p7) was conducted at 64 sites across 14 countries (Appendix p 2). This study was conducted in 
accordance with the International Council for Harmonisation Good Clinical Practice and the ethical principles 
outlined in the Declaration of Helsinki.19 Study ethical approval was obtained at all sites; the first ethical 
approval was obtained on 22 May 2015 for investigational sites in Canada (Schulman Associates Institutional 
Review Board, Inc). The full protocol is available on Clinicaltrials.gov: 
https://clinicaltrials.gov/ProvidedDocs/71/NCT02504671/Prot_000.pdf. Key protocol amendments are listed in 
Appendix p2.  
 
Patients 
Patients aged ≥18 years, with a clinical diagnosis of RA according to ACR/EULAR 2010 classification 
criteria,20 receiving MTX and with a disease duration ≥12 weeks were eligible. All patients provided written 
informed consent. 
Patients were required to have Functional Class I, II or III (1992 ACR Classification of Functional Status in 
RA,21 swollen joint count in 66 joints (SJC66) ≥4, tender joint count in 68 joints (TJC68) ≥4 at screening and at 
day 1, DAS28(CRP) ≥3ꞏ2 at screening or DAS28 with erythrocyte sedimentation rate ≥3ꞏ2 at day 1. For 
pulmonary safety, patients were required to have diffusing capacity or transfer factor of the lung for carbon 




Patients with a history of other inflammatory rheumatologic or autoimmune disorders, clinically significant or 
unstable persistent cough or unexplained dyspnoea were excluded. See Appendix p2–5 for full eligibility 
criteria.  
Randomisation and masking 
Patients were randomised (1:1:1:1:1:1) to six treatment groups: placebo or otilimab 22ꞏ5, 45, 90, 135 or 180 mg. 
Randomisation was blocked (block size six). Patients were assigned to treatment using central randomisation 
according to a schedule generated by the study sponsor using validated software. Randomisation numbers were 
assigned using an interactive response technology system. Randomisation was not stratified. Patient recruitment 
was performed by study investigators. To ensure blinding of treatment assignments during the study, an 
unblinded administrator (study co-ordinator or nurse) prepared and administered the study drug. Further 
information on blinding is provided in Appendix p5. 
Procedures  
Treatments were administered subcutaneously once weekly for the first 5 weeks, then every other week (EOW) 
from week 6 until week 50. The rationale for dose selection and guidelines for treatment withdrawal or 
interruption are provided in Appendix p5–6. A 12-week safety follow-up period began after the final dose. All 
patients continued to receive MTX 7ꞏ5–25 mg/week and folic (or folinic) acid ≥5 mg/week during the treatment 
period. 
Patients not randomised to otilimab 180 mg escaped in an automated blinded procedure to otilimab 180 mg if 
they did not achieve a good/moderate EULAR response at week 12 or had DAS28(CRP) >3ꞏ2 at week 24. Any 
patients who did not achieve EULAR good/moderate response at week 36 were withdrawn from treatment at the 
next visit in an automated procedure. 
Efficacy outcomes, Health Assessment Questionnaire-Disability Index (HAQ-DI) score, pain Visual Analogue 
Scale (VAS), and Patient’s Global Assessment of Arthritis Disease Activity (PtGA) were assessed at screening, 
baseline (day 1), weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52, and at follow-up (week 62). 
Brief Fatigue Inventory – Question 3 (BFI-Q3), Functional Assessment of Chronic Illness Therapy (FACIT)-
Fatigue, and 36-item short-form health survey (SF-36) were assessed at baseline, weeks 4, 12, 24, 36, and 52, 
and at follow-up. Blood samples for pharmacokinetic (PK) and biomarker outcomes were taken at baseline, 
weeks 1, 2, 4, 6, 8, 12, 24, 36, and 52, and at follow-up; additional blood samples for PK analysis only were 
taken at weeks 16 and 20.  
Safety parameters were monitored throughout the study until follow-up, including monitoring of AEs, SAEs, 
AEs of special interest (AESI), infections, and immunogenicity. The following pulmonary assessments were 
performed at screening, day 1, week 12, 24, 36, and 52, and follow-up: chest X-ray at screening, cough, Borg 
dyspnoea questionnaire, lung auscultation, pulse oximetry throughout the study, spirometry (FEV1, forced vital 
capacity), and DLCO. Laboratory monitoring for haematology and chemistry was performed at screening, week 
2,4, 8, 12, 16, 20, 24, 32, 42, and at follow-up; urinalysis was performed at the same time points, excluding 
week 2; cholesterol, triglycerides, and lipoproteins were assessed at screening, week 12, and 24, and follow-up.  
Outcomes  
The primary endpoint was the proportion of patients who achieved DAS28(CRP) remission (DAS28[CRP] 
˂2ꞏ6) at week 24. 
Secondary endpoints were: change from baseline (CFB) in DAS28(CRP) at week 12 and all other assessment 
time points; proportion of patients who achieved DAS28(CRP) remission at all time points; time to first 
DAS28(CRP) remission; ACR20/50/70 and good/moderate EULAR response rate at all time points; index- and 
Boolean-based ACR/EULAR remission rates, and CDAI remission rate at all time points; CFB in SJC66, 
TJC68, Simple Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI); CFB in PROs at all 
time points using HAQ-DI score, pain VAS, physical and mental component of SF-36, FACIT-Fatigue, and 
BFI-Q3. PK was assessed as a secondary objective; endpoints were: otilimab serum concentration and 
evaluation of the target engagement biomarkers free soluble GM-CSF and soluble GM-CSF complexed to 
otilimab (GM-CSF/otilimab complex). 
Secondary safety endpoints were incidence of AEs and SAEs, infections, and pulmonary events. Any new or 
clinically significant pulmonary abnormalities (e.g. increased dyspnoea, unexplained and persistent coughing, or 
>15% relative decrease in DLCO from baseline) were referred to a pulmonologist for further assessment in order 






Based on a Fisher’s exact test, a planned sample size of 35 patients per group provided ~90% power to detect a 
difference of 30% in the proportion of patients achieving DAS28(CRP) remission at week 24 between each 
otilimab dose and placebo at the 2-sided α=0ꞏ05 level (33% vs 3%). The difference of 30% between groups was 
based on the expected clinical profile for otilimab; the predicted placebo rate of 3% was based on the literature 
review of current therapies presenting DAS28(CRP) remission results. The efficacy and safety population was 
the intent-to-treat (ITT) population: all randomised patients who received ≥1 dose of study drug. The PK 
population was all randomised patients who received ≥1 dose of otilimab and had ≥1 quantifiable otilimab 
concentration available.  
Binary endpoints, including the primary endpoint, were assessed using a logistic regression model adjusted for 
treatment group and appropriate baseline scores. A non-responder imputation was used for patients with missing 
efficacy data and those who escaped to otilimab 180 mg dose.  
All continuous efficacy endpoints, including patient-reported outcomes such as VAS, HAQ-DI, SF-36, and 
FACIT-Fatigue, were analysed using mixed model repeated measures with fixed effects for treatment group and 
baseline value. CFB will be missing at visits with missing post-baseline values, and all patients who escaped to 
otilimab 180 mg were set to missing post escape. The serum otilimab and target engagement biomarker 
concentrations were summarised by descriptive statistics by treatment group and visit through week 52. A post 
hoc analysis was performed to evaluate the percentage of patients with pain improvement ≥minimal clinically 
important difference (MCID; 10 mm difference on 100 mm VAS).  
Two interim analyses were planned. Interim 1 and 2 were conducted when 90 subjects completed week 4 and 
12, respectively, to evaluate whether to terminate the study based on the dose response relationship in CFB in 
DAS28(CRP). Interim 2 also evaluated the predictive probabilities of observing a 25% difference at week 24 in 
DAS28(CRP) remission and the whether there was a need to terminate individual dose treatment arms. 
Following the interim analyses, the study was not stopped and there were no changes made to the treatment 
arms.  
All analyses were conducted using SAS v9ꞏ3 (SAS Institute Inc., Cary, NC, USA). This study (BAROQUE, 
GSK study number 201755) is registered with ClinicalTrials.gov, NCT02504671. An independent data 
monitoring committee monitored the study.  
 
Role of the funding source 
This study (GSK study 201755; NCT02504671) was sponsored by GSK, which was involved in study design 
and conduct together with authors and investigators. Clinical data were collected by investigators and their 
teams, and GSK. All authors, including those employed by the funder, were involved in data analysis, 
interpretation of results and the preparation, review and approval of this manuscript. All authors had full access 
to all the data in the study, contributed to writing/reviewing of the report, and approved the final submitted 
version. The corresponding author had the final responsibility to submit for publication. 
RESULTS 
The study began on 23 July 2015 and completed on 29 December 2017. Of 526 patients with RA who were 
screened, 222 met the inclusion criteria and were randomised. A large proportion of patients escaped to the 
180 mg dose at week 12 (Figure 1). No protocol violations impacted the interpretation of the study results 
(Appendix p13). 
Baseline demographics, disease activity characteristics and PRO measures were balanced across treatment 
groups (Table 1), other than a higher proportion of female (180/222 [81%]) patients, which is typical for an RA 
population, and a slight imbalance in CRP, which was higher in the otilimab 22ꞏ5 mg group compared with 
other groups. Mean (standard deviation [SD]) age was 50ꞏ5 (11ꞏ27) years. Although the inclusion criteria 
allowed moderate-to-severe RA, baseline disease characteristics were indicative of severe RA: mean (SD) 
DAS28(CRP) was 6ꞏ19 (0ꞏ836) and mean (SD) disease duration ranged from 5ꞏ1 (6ꞏ4) years (45 mg group) to 
7ꞏ7 (7ꞏ1) years (180 mg group). Mean (SD) CDAI was 44ꞏ31 (12ꞏ824). Mean (SD) pain VAS score was 67ꞏ0 
(18ꞏ49); mean (SD) HAQ-DI score was 1ꞏ755 (0ꞏ556), and mean (SD) FACIT-Fatigue score was 25ꞏ7 (9ꞏ82). 
At week 24, DAS28(CRP) <2ꞏ6 remission rates were consistently higher for all otilimab dose groups versus 
placebo, but none were statistically significant. The difference to placebo in DAS28(CRP) remission rate was 
2ꞏ7–16ꞏ2%; the biggest difference was achieved with otilimab 90 mg (16ꞏ2%; odds ratio [OR] 8ꞏ39; 95% 




rapid for all otilimab dose groups, followed by a slower rate of improvement from week 6 to 12. Based on the 
patients originally randomised to otilimab 180 mg, the improvement in DAS28(CRP) reached a plateau between 
weeks 12 and 24 (Figure 2B). A post hoc analysis indicated that, at week 24, the proportion of patients 
achieving DAS28(CRP) low disease activity (≤3ꞏ2) generally increased with increasing dose (Appendix p14). 
There was a significant difference in DAS28(CRP) mean CFB between the 180 mg group and placebo at week 
12 (−1ꞏ27 [95% CI −1ꞏ91, 0ꞏ63]; p=0ꞏ0001) and week 24 (−1ꞏ82 [95% CI −2ꞏ75, −0ꞏ89]; p=0ꞏ0002) (Appendix 
p15–16). Dose-response modelling for CFB in DAS28(CRP) at week 12 was conducted using a linear log-dose 
model; the model-predicted DAS28(CRP) response for otilimab 180 mg was −1ꞏ19 (95% CI −1ꞏ75, −0ꞏ63). 
Time to first DAS28(CRP) remission was shortest in the otilimab 90 mg dose group: mean (SD) 8ꞏ91 (4ꞏ022) 
weeks. 
Given that a substantial number of patients had escaped to the 180 mg dose at week 12 and that target saturation 
was not achieved after week 8 (as described below), subsequent analyses included data up to and including the 
week 12 time point. Secondary endpoint data for all timepoints up to week 12 are provided in Appendix p17–
28. 
At week 12, significantly more patients receiving any otilimab dose achieved an ACR20 response versus 
placebo, and significantly greater response rates in ACR50 were achieved with the 45 mg and 135 mg doses 
versus placebo; there was no significant difference between placebo and otilimab groups for ACR70 response 
rate (Figure 2C). At week 12, good/moderate EULAR response rate was higher in the otilimab groups versus 
placebo. The highest proportion of patients with a good/moderate EULAR response was in the otilimab 180 mg 
group: 28/37 (76%); difference versus placebo 54ꞏ1% (95% CI 34ꞏ9, 73ꞏ2) OR 10ꞏ93 (95% CI 3ꞏ68, 32ꞏ51) 
p<0ꞏ0001. CDAI remission rate at week 12 was highest in the otilimab 90 mg dose group: difference versus 
placebo 8ꞏ1% (95% CI –3ꞏ2 to 19ꞏ7). Index- (SDAI ≤3ꞏ3) and Boolean-based ACR/EULAR remission rates 
could not be assessed due to low numbers of responders. 
There was a rapid and substantial improvement in SJC66, TJC68, CDAI (Appendix p8) and SDAI in all 
otilimab dose groups versus placebo. For SJC66, there was a significant difference versus placebo in least 
squares (LS) mean CFB to week 12 in the 180 mg group (−7ꞏ54 [95% CI −11ꞏ78, −3ꞏ30; p=0ꞏ0006]) and the 
90 mg group (−5ꞏ63 [95% CI −9ꞏ85, −1ꞏ41; p=0ꞏ0092]). For TJC68, the biggest difference versus placebo in LS 
mean CFB to week 12 was in the 180 mg group (−8ꞏ91 [95% CI –14ꞏ72, –3ꞏ10; p=0ꞏ0028]). The greatest 
change in CDAI from baseline at week 12 was observed in the otilimab 180 mg dose group, with a difference 
versus placebo of −16ꞏ63 (95% CI −23ꞏ97, −9ꞏ30; p<0ꞏ0001). For SDAI, the biggest difference versus placebo 
in LS mean CFB to week 12 was in the 180 mg group (–16ꞏ86 [95% CI –24ꞏ39, –9ꞏ32; p<0ꞏ0001). A sustained 
reduction in CRP levels from baseline to week 12 of ~50% was evident in otilimab dose groups of 45 mg and 
above, although these changes were not statistically significant versus placebo (Appendix p8).  
Early, consistent and sustained (up to week 12) improvements from baseline were observed in all PRO measures 
(Figure 3, Appendix p9–10). By week 4 there was a significant difference in LS mean CFB in patient’s 
assessment of pain (VAS) versus placebo for all doses of otilimab (except for the 22ꞏ5 mg and 135 mg doses). 
At week 12 there was a significant difference in pain versus placebo for all doses except for the 22ꞏ5 mg dose; 
the largest differences versus placebo were in the 90 mg dose group (−18ꞏ18 [95% CI −28ꞏ35, −8ꞏ01]; 
p=0ꞏ0005) and the 180 mg dose group (–17ꞏ94 [95% CI –28ꞏ18, –7ꞏ70]; p=0ꞏ0007) (Figure 3A). A post hoc 
analysis revealed that overall, otilimab treatment was associated with a higher proportion of patients with pain 
improvement ≥10 mm difference on 100 mm VAS (minimal clinically important difference; MCID) versus 
placebo, with the largest difference versus placebo in the 180 mg dose group at week 12 (46% [95% CI 22%, 
69%]) (Appendix p29).  
Although there were no statistically significant differences between otilimab dose groups and placebo in mean 
HAQ-DI scores at weeks 4 and 12, a MCID versus placebo was observed at week 12 in the 180 mg dose group 
(−0ꞏ24 [95% CI −0ꞏ49, 0∙01; p=0ꞏ0585]) (Figure 3B). At week 12, treatment with otilimab was associated with 
significant improvements in PtGA in all dose groups from 45 mg and above versus placebo; the largest 
difference versus placebo was observed with the 90 mg dose (−17ꞏ40 [95% CI −27ꞏ44, −7ꞏ35]; p=0ꞏ0008) and 
the difference between 180 mg and placebo was −17ꞏ18 (95% CI −27ꞏ27, −7ꞏ10; p=0ꞏ0009) (Figure 3C). A 
dose-dependent decrease was observed in fatigue (FACIT-Fatigue) from week 4, reaching a statistically 
significant improvement at week 12 with the 180 mg dose (difference from placebo: 5ꞏ33 [95% CI 1ꞏ77, 8ꞏ89]; 
p=0ꞏ0035) (Figure 3D). There were statistically significant differences over placebo in BFI-Q3 with all doses 
from 45 mg at week 12. The largest difference from placebo in BFI-Q3 to week 12 was observed in the 180 mg 
dose group (95% CI −1ꞏ57 [−2ꞏ53, −0ꞏ62]; p=0ꞏ0013) (Appendix p10).  
There was a dose-dependent improvement in SF-36 scores, observed in all SF-36 domains (general health, 




with all doses of otilimab at week 12 compared with placebo (except for the 22ꞏ5, 45, and 90 mg dose groups in 
the social functioning domain). For the otilimab 180 mg dose the difference versus placebo in SF-36 physical 
score was 4ꞏ11 (95% CI 1ꞏ22, 7ꞏ01; p=0ꞏ0056) at week 4 and 3ꞏ55 (95% CI 0ꞏ22, 6ꞏ88; p=0ꞏ0367) at week 12 
(Appendix p9). Consistent with results from VAS assessment of pain, there was a significant improvement in 
SF-36 bodily pain scores at week 4 (otilimab 180 mg difference vs placebo: 5ꞏ08 [95% CI 2ꞏ14, 8ꞏ03; 
p=0ꞏ0008]); the improvement over placebo was observed up to week 12 for otilimab 180 mg, although 
statistical significance was not reached at this time point (difference vs placebo 3ꞏ43 [95% CI –0ꞏ13, 6ꞏ99; 
p=0ꞏ0586]). There were no notable differences observed in SF-36 mental score at week 4; however, 
improvements were observed at week 12 for all doses, but these did not reach statistical significance. The 
difference versus placebo for 180 mg dose was 0ꞏ10 (95% CI −4ꞏ01, 4ꞏ20; p=0ꞏ9636) at week 4 and 3ꞏ25 (95% 
CI −1ꞏ05, 7ꞏ54; p=0ꞏ1378) at week 12.  
The mean serum concentration of otilimab increased in a dose-dependent manner and peaked at week 4; the 
decline in serum concentrations coincided with the transition to EOW dosing from week 6 (Appendix p11). In 
the 180 mg group, observed mean trough concentration was 713–936 ng/mL between week 8 and week 52 
(Appendix p12). The otilimab trough concentrations were lower than predicted from historic PK data (GSK 
unpublished results). Consistent with PK observations, the concentration of GM-CSF/otilimab complex also 
increased in a dose-dependent manner, peaking at week 4, and then declined after the switch to EOW dosing 
after week 6 (Appendix p11). Separation between the 135 mg and 180 mg dose and overall decline was 
observed from week 8, suggesting the target was no longer saturated. 
AE rates were balanced across all treatment groups and most AEs were mild or moderate (Table 2). No dose 
effect on AEs or other safety parameters were observed in the otilimab groups. The most common treatment-
related AEs were nasopharyngitis, upper respiratory tract infection and anaemia pre-escape, and nasopharyngitis 
and upper respiratory tract infection post escape. The rates of cytopenia and serious infections were low and 
there was no significant incidence of anti-drug antibodies across treatment groups. There were no deaths, 
malignancies, or venous thromboembolism, nor any events of pulmonary toxicity of clinical concern. Changes 
in DLCO were infrequent and small; persistent (≥15 days) DLCO decrease from baseline >15% was observed in 
one patient in each otilimab treatment group (except 90 mg) pre-escape, and in six patients post escape (two 
patients in each of the groups originally randomised to placebo, 22ꞏ5 mg and 135 mg). These changes were not 
considered to be dose related or clinically significant. Persistent dyspnoea was experienced by one patient in the 
otilimab 90 mg group, pre-rescue, beginning on day 8; the patient showed no decrease in DLCO, and no 
substantial change in FEV1 and forced vital capacity between baseline and week 12. Pulmonary events led to 
treatment discontinuation in three patients. Mild pulmonary fibrosis was reported in one patient in the otilimab 
22ꞏ5 mg group, which occurred post escape to 180 mg dose. One patient in the otilimab 180 mg group 
experienced mild persistent DLCO decrease, which was associated with acute bronchitis. Mild persistent 
dyspnoea was reported in one patient in the placebo group after escape to otilimab 180 mg dose: no decrease in 
DLCO was observed and a small (<5%) decrease in spirometry assessments was reported; the event was assessed 
as not related to study medication. None of the pulmonary events were assessed as pulmonary alveolar 
proteinosis.  
Pre-escape, eight patients experienced nine AESIs: injection-site reactions, neutropaenia, serious infection, 
persistent dyspnoea, and persistent cough (Appendix p30). There were six post-escape AESIs reported by four 
patients during the study period: injection-site reactions and persistent dyspnoea (Appendix p30). There were 
no events of hypersensitivity reactions, opportunistic infections, or pulmonary alveolar proteinosis reported.  
Six patients experienced SAEs pre-escape (foot fracture, arthralgia, myocardial infarction, oesophageal spasm, 
acute pyelonephritis, uterine leiomyoma, and dizziness; none were reported in the otilimab 180 mg or placebo 
groups) (Appendix p31). After escape to the 180 mg group, one event each of ankle fracture and RA were 
reported in the placebo and 135 mg groups, respectively. None of the SAEs (pre- or post-escape) were deemed 
to be related to study treatment. 
DISCUSSION 
In this Phase IIb dose-ranging study, the primary endpoint at week 24 was not achieved. Patients had severe RA 
at baseline, characterised by higher DAS28(CRP), pain and HAQ-DI levels compared with recent Phase IIb 
studies targeting GM-CSF.16 Despite this high baseline disease severity, otilimab in combination with MTX 
demonstrated clinically meaningful efficacy over 12 weeks of treatment with a rapid reduction in DAS28(CRP) 
similar to other approved biologic agents,22,23 and the treatment was well tolerated.  
The primary endpoint of DAS28(CRP) remission was chosen based on its importance as a EULAR treatment 




treatment would continue treatment at the randomised dose throughout the study.24 This was based on the 
rationale that an optimised ‘treat-to-target’ dosing regimen may result in a higher proportion of patients 
achieving remission.24 Indeed, the clinical benefit of frequent monitoring and treatment adjustments according 
to a prespecified target has been demonstrated in other randomised trials.25  
Otilimab serum concentrations were lower than expected based on historic data from healthy volunteers (GSK 
data on file), resulting in suboptimal exposure during EOW dosing, from week 6 onwards. This discrepancy is 
likely due to the high apparent clearance of otilimab.26 Consistent with this, levels of serum GM-CSF/otilimab 
complex showed that full target engagement was not achieved from week 6 onwards with EOW dosing. The 
findings confirm and extend those from a Phase IIa study (RENAISSANCE, GSK study 205180; 
ClinicalTrials.gov Identifier: NCT02799472), which assessed otilimab 180 mg compared with placebo in 
patients with RA receiving concomitant MTX over 12 weeks.14 
Previous studies have shown that even among patients who achieve low disease activity, many still report 
significant pain that negatively affects their quality of life and may produce biologic, psychological, and social 
changes that could influence the future response to painful stimuli.2,3,27 Consequently, pain is prioritised by 
patients with RA as a key unmet need.2 Despite suboptimal pharmacological exposure with bi-weekly otilimab 
doses, and our study not reaching statistical significance for its primary endpoint of DAS28(CRP) <2ꞏ6 
remission, there was a rapid, sustained, and consistent improvement in all PRO endpoints. In particular, the 
improvement in pain VAS score was significantly greater than placebo at doses ≥45 mg at weeks 8 and 12. 
Similarly, there were substantial improvements in other PRO measures, including function, disability, health-
related quality of life, and fatigue. Of note, the 90 mg dose group had fewer patients who escaped to the 180 mg 
dose and trended towards better clinical outcomes compared with the 135 mg dose group. A slight imbalance in 
balance disease characteristics was also observed between these groups. Although this finding was investigated, 
no explanation was found. We may postulate that it could be an artefact of the small sample size or the baseline 
characteristics, but this is not confirmed. 
The pathophysiology of RA is complex, and the biological basis of joint pain could in part be different from that 
of inflammation and bone damage.2,5,10 Recent studies have shown that discrete subsets of synovial fibroblasts 
and macrophages that reside in distinct anatomical compartments of the joint are responsible for inflammation, 
tissue damage, and repair.28,29 These observations have provided a cellular basis for the partial dissociation of 
inflammation and damage in RA and osteoarthritis. However, there has not been any formal exploration in a 
clinical study of the mechanisms by which disease activity, remission, and pain relate to each other in either RA 
or osteoarthritis. Traditional anti-TNF therapies reduce inflammation and halt bone destruction,30 but may not 
target all the cell types associated with pain. GM-CSF plays a key role in the development of inflammatory and 
arthritic pain,5 and inhibition of the GM-CSF→JMJD3→ IRF4→ CCL17 (granulocyte-macrophage colony-
stimulating factor→jumonji domain-containing protein 3→interferon regulatory factor 4→chemokine [c-c 
motif] ligand 17) pathway ameliorates pain in osteoarthritis.10 In the current study, while the improvement in 
pain was accompanied by decreased inflammation, as evidenced by reduced CRP (and SJC) at week 12, our 
findings suggest that the therapeutic response with otilimab is predominantly driven by improvements in clinical 
parameters, reflected by the large CDAI responses not influenced by CRP changes. Indeed, the beneficial effect 
of otilimab on pain continued to progress beyond CRP reduction. These findings raise the possibility that the 
impact of treatment on pain and inflammation may be partly dissociated in RA; further studies are required to 
explore this more fully.  
One limitation was that the design resulted in a high percentage of escape from the placebo and the lower 
otilimab dose groups after week 12. As such, the nonsignificant difference versus placebo in DAS28(CRP) at 
week 24 should be interpreted with consideration of a large proportion of patients in the placebo group having 
received otilimab 180 mg. The high percentage of escape, together with lower than expected exposure of 
otilimab, is likely to have contributed to the relatively low patient numbers and remission rates at the primary 
endpoint, week 24. Despite this, the observed improvements in disease activity and the rapid reduction of 
associated pain over 12 weeks reflects important clinical benefits, especially for patients with long-standing 
active disease.2 Phase III studies are underway to further establish the efficacy of otilimab in a larger population 
and over a longer period, using an optimised dose and regimen26 (ClinicalTrials.gov Identifiers: NCT03980483, 
NCT03970837 and NCT04134728). 
The study design allowed the safety of otilimab to be assessed over 50 weeks of treatment and 12 weeks of 
subsequent follow-up. No significant unexpected safety findings were observed. Otilimab was well tolerated, 
with low rates of cytopenia and serious infections, no significant incidence of anti-drug antibodies, no deaths 
and no pulmonary toxicity events of clinical concern (including pulmonary alveolar proteinosis), consistent with 




In conclusion, despite the suboptimal level of exposure with bi-weekly dosing from week 6, otilimab 
demonstrated significant reductions in RA disease activity at week 12, particularly on joint swelling and 
tenderness and PROs involving pain. The results of this study support further clinical development given the 
observed benefit:risk of inhibiting GM-CSF with otilimab in the treatment of active RA. Furthermore, they 
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FIGURES AND TABLES 
Figure 1. Patient disposition.  
 
*Patients could be excluded for multiple reasons. 
DAS28, Disease Activity Score for 28 different joints; DLCO, diffusing capacity or transfer factor of the lung for 
carbon dioxide; EULAR, European League Against Rheumatism; FEV1, forced expiratory volume in 1 second; 





Figure 2. (A) DAS28(CRP) <2ꞏ6 remission rate at week 24 (B) DAS28(CRP) CFB over 24-week treatment 





DAS28 (CRP) <2ꞏ6 remission rate at week 24 and ACR response at week 12 (binary endpoints) were analysed 
using logistic regression model by visit with fixed effects for treatment group and appropriate baseline score; 
non-responder imputation was used for patients with missing efficacy data and those who escaped to otilimab 
180 mg dose. 
DAS28 (CRP) CFB over the 24-week treatment period (continuous endpoint) was analysed using repeated 
measures analysis adjusted for DAS28(CRP) BL score, treatment group, visit and treatment group by visit, and 
BL by visit interactions. Patients who escaped to otilimab 180 mg at week 12 were set to missing. Data post-
week 24 were excluded due to quantity of missing data. Values on graph are LS mean CFB at week 4, week 12, 
and week 24. 
*p<0ꞏ05; **p<0ꞏ02; ***p<0ꞏ01; ****p<0ꞏ001 vs placebo.  
ACR, American College of Rheumatology; BL, baseline; CFB, change from baseline; CI, confidence interval; 
CRP, C-reactive protein; D, day; DAS28, Disease Activity Score for 28 different joints; EOW, every other 





Figure 3. LS mean CFB in (A) pain (B) HAQ-DI (C) PtGA (D) FACIT-Fatigue over time (ITT 
population).                
 
 
*p<0ꞏ05; **p<0ꞏ01; ***p<0ꞏ001 vs placebo. 
Repeated measures analysis adjusted for BL, treatment group, visit and treatment group by visit and BL by visit 
interactions. 
Values on graph are LS mean CFB at W4 and W12. For FACIT-Fatigue higher scores indicate better quality of 
life. Pain and PtGA were assessed by VAS. 
BL, baseline; CFB, change from baseline; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, 
Health Assessment Questionnaire-Disability Index; ITT, intent-to-treat; LS, least squares; PtGA, Patient’s 





Table 1. Baseline patient demographics and clinical characteristics. 
 





45 mg (n=37) 90 mg (n=37) 135 mg (n=37) 180 mg (n=37) 
Age (years), mean (SD) 50ꞏ0 (11ꞏ3) 48ꞏ4 (11ꞏ3) 52ꞏ8 (12ꞏ2) 52ꞏ7 (11ꞏ3) 47ꞏ1 (10ꞏ0) 52ꞏ3 (10ꞏ8) 
Female, n (%) 28 (76) 30 (81) 33 (89) 27 (73) 33 (89) 29 (78) 
RA diagnosis (years), mean (SD) 6ꞏ2 (7ꞏ9) 6ꞏ3 (6ꞏ8) 5ꞏ1 (6ꞏ4) 6ꞏ1 (6ꞏ0) 6ꞏ9 (5ꞏ6) 7ꞏ7 (7ꞏ1) 
ACPA positive, n (%) 28 (76) 24 (65) 24 (65) 23 (62) 28 (76) 30 (81) 
RF positive, n (%) 28 (76) 26 (70) 27 (73) 21 (57) 22 (59) 30 (81) 
DAS28(CRP), mean (SD) 6ꞏ2 (0ꞏ8) 6ꞏ4 (0ꞏ8) 6ꞏ1 (0ꞏ7) 6ꞏ2 (0ꞏ8) 6ꞏ3 (0ꞏ9) 6ꞏ0 (0ꞏ9) 
SDAI (0-86), mean (SD) 47ꞏ4 (13ꞏ3) 48ꞏ0 (12ꞏ9) 45ꞏ2 (12ꞏ0) 46ꞏ5 (13ꞏ0) 48ꞏ2 (14ꞏ6) 44ꞏ4 (14ꞏ0) 
CDAI (0-76), mean (SD) 45ꞏ7 (13ꞏ5) 45ꞏ2 (11ꞏ8) 42ꞏ8 (12ꞏ1) 44ꞏ5 (12ꞏ6) 45ꞏ3 (13ꞏ5) 42ꞏ5 (13ꞏ9) 
TJC68, mean (SD) 28ꞏ5 (13ꞏ6) 27ꞏ9 (12ꞏ1) 26ꞏ1 (14ꞏ1) 28ꞏ8 (14ꞏ8) 30ꞏ1 (14ꞏ8) 25ꞏ3 (12ꞏ4) 
SJC66, mean (SD) 18ꞏ5 (9ꞏ3) 17ꞏ7 (8ꞏ5) 17ꞏ2 (8ꞏ9) 18ꞏ3 (10ꞏ1) 18ꞏ9 (10ꞏ2) 18ꞏ9 (10ꞏ1) 
Pain (100 mm VAS), mean (SD) 66ꞏ1 (16ꞏ7) 71ꞏ2 (15ꞏ8) 70ꞏ1 (17ꞏ3) 65ꞏ8 (20ꞏ4) 67ꞏ1 (19ꞏ3) 61ꞏ6 (20ꞏ6) 
PtGA (100 mm VAS), mean 
(SD) 
66ꞏ0 (15ꞏ6) 72ꞏ5 (14ꞏ2) 71ꞏ6 (14ꞏ9) 68ꞏ2 (17ꞏ6) 69ꞏ6 (17ꞏ0) 63ꞏ2 (16ꞏ6) 
PhGA (100 mm VAS), mean 
(SD) 
64ꞏ2 (11ꞏ9) 67ꞏ5 (10ꞏ3) 67ꞏ1 (15ꞏ9) 65ꞏ9 (18ꞏ6) 67ꞏ2 (15ꞏ4) 64ꞏ1 (15ꞏ7) 
FACIT-Fatigue, mean (SD)  24ꞏ7 (8ꞏ59) 25ꞏ9 (9ꞏ13) 26ꞏ5 (9ꞏ22) 25ꞏ1 (9ꞏ89) 24ꞏ3 (9ꞏ55) 27ꞏ6 (12ꞏ35) 
BFI-Q3, mean (SD) 6ꞏ5 (1ꞏ91) 6ꞏ5 (2ꞏ17) 6ꞏ5 (2ꞏ04) 6ꞏ7 (2ꞏ08) 6ꞏ6 (1ꞏ91) 5ꞏ8 (2ꞏ51) 
HAQ-DI, mean (SD) 1ꞏ77 (0ꞏ6) 1ꞏ72 (0ꞏ5) 1ꞏ88 (0ꞏ4) 1ꞏ3 (0ꞏ5) 1ꞏ80 (0ꞏ6) 1ꞏ63 (0ꞏ7) 
SF-36 (Mental Score), mean 
(SD) 
42ꞏ5 (9ꞏ4) 41ꞏ8 (9ꞏ9) 42ꞏ3 (9ꞏ4) 40ꞏ7 (10ꞏ4) 41ꞏ4 (12ꞏ6) 41ꞏ3 (13ꞏ1) 
SF-36 (Physical Score), mean 
(SD) 
29ꞏ0 (5ꞏ6) 28ꞏ6 (6ꞏ1) 28ꞏ6 (7ꞏ0) 30ꞏ2 (6ꞏ6) 28ꞏ5 (7ꞏ0) 31ꞏ8 (7ꞏ9) 
hsCRP (mg/mL), median (range) 12ꞏ9 (2–66) 19ꞏ5 (3–135) 14ꞏ7 (1–158) 13ꞏ7 (1–99) 15ꞏ6 (1–261) 12ꞏ7 (2–103) 
Prior DMARD medications, n 
(%) 
      
Methotrexate, methotrexate 
sodium 
36 (97) 37 (100) 37 (100) 37 (100) 37 (100) 36 (97) 
Sulfasalazine 5 (14) 6 (16) 3 (8) 8 (22) 9 (24) 6 (16) 
Leflunomide 1 (3)  4 (11) 3 (8) 3 (8) 8 (22) 4 (11) 
Hydroxychloroquine 2 (5) 2 (5) 4 (11) 1 (3)  3 (8) 2 (5) 
Azathioprine 1 (3)  0 0 1 (3)  0 0 
Chloroquine + chloroquine 
phosphate + chloroquine sulfate 
2 (5)  2 (5)  0 1 (3)  3 (8) 1 (3)  
Adalimumab 0 0 0 1 (3) 0 0 
Oral glucocorticoids       
Oral glucocorticoid use, n (%) 15 (40) 24 (65) 20 (54) 22 (59) 21 (57) 22 (59) 
Oral glucocorticoid dose 
(prednisolone equivalent, 
mg/day), mean (SD) 
6ꞏ37 (2ꞏ1) 6ꞏ04 (2ꞏ9) 6ꞏ83 (2ꞏ6) 6ꞏ75 (3ꞏ0) 5ꞏ90 (3ꞏ2) 5ꞏ89 (2ꞏ7) 
ACPA, Anti-cyclic citrullinated protein antibody; BFI-Q3, Brief Fatigue Inventory-Question 3; CDAI, Clinical 
Disease Activity Index; DAS28(CRP), disease activity score for 28 different joints with C-reactive protein 
value; DMARD, Disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire-Disability 
Index; hsCRP, high sensitivity CRP; PhGA, physician’s global assessment of arthritis; PtGA, patient’s global 
assessment of arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SDAI, 
Simplified Disease Activity Index; SJC66, swollen joint count for 66 different joints; TJC68, tender joint count 





Table 2. Adverse events (ITT population). 
 
Pre-escape, n (%) [#]*  Otilimab 
Placebo (n=37) 22ꞏ5 mg (n=37) 45 mg (n=37) 90 mg (n=37) 135 mg (n=37) 180 mg (n=37) 
Any AEs 18 (49) [27] 19 (51) [36] 24 (65) [59] 22 (59) [54] 19 (51) [48] 24 (65) [64] 
AEs leading to discontinuation of 
study medication 
0 0 0 2 (5) [2] 0 2 (5) [2] 
SAEs 0 2 (5) [2] 1 (3) [1] 2 (5) [3] 1 (3) [1] 0 
Treatment-related AEs 2 (5) [2] 9 (24) [15] 6 (16) [13] 6 (16) [7] 5 (14) [7] 9 (24) [19] 
Most common AEs†       
Nasopharyngitis 1 (3) [1] 3 (8) [3] 7 (19) [10] 3 (8) [3] 6 (16) [6] 9 (24) [12] 
Upper respiratory tract infection 3 (8) [3] 2 (5) [2] 1 (3) [1] 2 (5) [2] 2 (5) [3] 3 (8) [4] 
Anaemia 0 2 (5) [2] 1 (3) [1] 0 2 (5) [3] 5 (14) [5] 
Alanine aminotransferase increase 0 1 (3) [1] 3 (8) [6] 2 (5) [2] 2 (5) [2] 0 
Post- escape, n (%) [#]* Placebo (n=33) 22ꞏ5 mg (n=30) 45 mg (n=27) 90 mg (n=25) 135 mg (n=28)  
Any AEs 22 (67) [50] 16 (53) [40] 11 (41) [47] 10 (40) [19] 17 (61) [38]  
AEs leading to discontinuation of 
study medication 
1 (3) [1] 1 (3) [1] 0 0 0  
SAEs 1 (3) [1] 0 0 0 1 (4) [1]  
Treatment-related AEs 5 (15) [6] 6 (20) [16] 4 (15) [20] 0 6 (21) [12]  
Most common AEs†       
Nasopharyngitis 7 (21) [7] 3 (10) [3] 1 (4) [1] 2 (8) [3] 2 (7) [2]  
Upper respiratory tract infection 0 3 (10) [4] 2 (7) [2] 0 5 (18) [6]  
Anaemia 0 1 (3) [1] 0 0 2 (7) [2]  
Alanine aminotransferase increase 2 (6) [2] 0 2 (7) [2] 1 (4) [1] 1 (4) [2]  
*n=number of patients with ≥1 event; #=number of individual occurrences. 
†AEs occurring in >5% of patients.  
AE, adverse event; ITT, intent-to-treat; SAE, serious adverse event. 
 
 
